NEW YORK, May 5, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc (“Zylö”).

(PRNewsfoto/Hoth Therapeutics Inc.)

Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. This small equity investment in Zylö is a further commitment to our belief in Zylö’s science and team.”

Stated Scott Pancoast, CEO of Zylö Therapeutics, “Partnering with Hoth in 2019 was an important step in propelling our lupus program forward. This equity investment in Zylö stock represents an expansion of the partnership and is a win-win for the two companies.” 

According to estimates by